Hints and tips:
...Immortality, Inc. , by Chip Walter, National Geographic Partners, RRP £17.99...
...Shares in Roche, whose subsidiary Genentech makes gantenerumab, were flat....
...Sam Kulkarni, Crispr chief, said the company was trying to follow the lead of Genentech, which rode the biotech boom to become one of the sector’s largest companies, while many others were sold off at low...
...Its multiple sclerosis treatment Tecfidera now has a rival from Genentech, and a muscular dystrophy drug Spinraza is expected soon to have a new rival from PTC Therapeutics....
...Meanwhile Mr O’Day will be replaced by Bill Anderson, head of Roche’s Genentech subsidiary, from the start of next year....
...months: Rituximab; another Roche drug, Trastuzumab, marketed as Herceptin and used to treat breast cancer; and Bevacizumab, marketed as Avastin, which is used to treat a number of cancers and is made by Genentech...
...On top of this, pioneers such as Genentech, with its genetically engineered insulin, were quick to bring drugs to the market, giving a boost to investor confidence that other countries lacked....
...“If this had happened at Genentech back in the day, they would probably have spent two years looking into this — not a week,” he says, referring to the biotech company set up to explore genetic medicine...
...Marc Tessier-Lavigne, a former Genentech executive, is president of Rockefeller, while Laurie Glimcher, his counterpart at Cornell, is a director at Bristol-Myers Squibb....
...Ms Du and others like her are aiming to replicate the success of US companies such as Genentech and Amgen, which suddenly appeared in the 1980s to become forces in global pharma....
...for 31 per cent of the money it put to work this year — also potentially puts it into competition with Calico, a division of Alphabet run by Art Levinson, a former chief executive of biotechnology group Genentech...
...Calico also hired Hal Barron, another Genentech veteran, to lead its R&D....
...But this month the California company went a step further in making its own push into drug development by hiring Richard Scheller, former head of research and development at Genentech, the biotech arm of...
...With Calico — short for the California Life Company — Google has reassembled some of the top talent from pioneering biotech company Genentech, including former chief executive Art Levinson....
...The recruitment of Richard Scheller, former head of R&D at Genentech, the biotech arm of Roche, sent a message that 23andMe was not content with supplying raw data to big pharma; it wanted to come up with...
...The agreed deal is Roche’s biggest since its $47bn takeover of Genentech, another US biotech company, in 2009 and marks its fourth acquisition this year as the group responds to investor pressure to put...
...Arthur Levinson, who built Genentech into one of the world’s biggest biotech groups before its takeover by Roche in 2009, is leaving because of a potential conflict with his role as chief executive of Google...
...But investors have been pressing the group to put more of its cash to work as it gradually pays off debt from its $47bn takeover of Genentech, the US biotech company, in 2009....
...That represents Roche’s busiest period of dealmaking since its $47bn takeover of Genentech in 2009....
...Genentech, for example, has a companion diagnostic test that determines whether a patient has the right “biomarker” to respond to a drug it is developing to treat bladder cancer....
...However, investors have been pressing Roche to put more of its cash to work as it gradually pays off debt from its $47bn takeover of Genentech, the US biotech company, in 2009....
...The boardroom shake-up is Apple’s first since Disney chief Bob Iger was appointed as a director in 2011, when Genentech’s Art Levinson was made chairman....
...Yet the former Genentech boss remains brutally exposed to the risks of drug development. While AstraZeneca spent a level $1.2bn on research and development in 2013, returns are ever harder to come by....
...James Hay, analyst at Brewin Dolphin, says Mr Soriot had been waiting a long time for a chance to run his own company after senior roles at Roche and before that at the Swiss group’s biotech subsidiary, Genentech...
...from the merger that created GlaxoSmithKline in 2000 and the $67bn purchase of Aventis by Sanofi in 2004, to Pfizer’s $68bn paid for Wyeth, Merck’s $41bn for Schering-Plough and Roche’s $47bn buyout of Genentech...
International Edition